Chidiac, Rony https://orcid.org/0000-0002-3642-0651
Abedin, Md.
Macleod, Graham https://orcid.org/0000-0001-6401-9307
Yang, Andy
Thibeault, Pierre E
Blazer, Levi L
Adams, Jarrett J
Zhang, Lingling
Roehrich, Heidi
Jo, Ha‐Neul
Seshagiri, Somasekar
Sidhu, Sachdev S https://orcid.org/0000-0001-7755-5918
Junge, Harald J https://orcid.org/0000-0003-2458-6010
Angers, Stephane https://orcid.org/0000-0001-7241-9044
Funding for this research was provided by:
Ministère du Développement économique, de la Création d'emplois et du Commerce | Ontario Ministry of Research and Innovation (RE07‐043)
Gouvernement du Canada | Canadian Institutes of Health Research (MOP‐136944)
Gouvernement du Canada | Canadian Institutes of Health Research (MOP‐84273)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT‐175160)
CFREF Medicine by Design (MBDC2‐2019‐03)
HHS | National Institutes of Health (R01 EY024261)
HHS | National Institutes of Health (P30 EY011374)
Article History
Received: 15 January 2021
Revised: 14 May 2021
Accepted: 17 May 2021
First Online: 9 June 2021
Conflict of interest
: LLB, JJA, SS, SSS, and SA are shareholders of AntlerA Therapeutics.